ERBB2 and adenocarcinoma: In the early stage GC, XELOX–trastuzumab was explored in the Spanish phase II trial NEOXH [15] as peri-operative treatment in 36 patients with HER2-positive gastric or EGJ resectable adenocarcinoma.